Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Mayo v. Prometheus: Thought Leaders Express Concern and Evaluate the Impact

Cells

The Mayo v. Prometheus event hosted at George Washington School of Law with the Biotechnology Industry Organization created an opportunity for a panel of thought leaders to distill meaning from the case, the impact on personalized medicine, and possible solutions to the Court created problem.* Is the decision a game-changer? Judge Paul R. Michel, former Chief Judge of the Court of Appeals for the Federal Circuit handling patent cases, concluded that the Mayo v. Prometheus Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: ,

Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward

gw-law

Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward is a public round-table event hosted by the Biotechnology Industry Organization and the George Washington University Law School. Guest speakers at the round-table will discuss implementation of the Prometheus decision in patent prosecution practice, in examination guidance in the United States Patent Office, and in patent litigation.  Speakers will also discuss the implications of the decision on personalized medicine and possible ways forward.  Speakers include: The Hon. Paul Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Congressional Hearing on International Patent Issues: BIO Submits Comments

ipday_2012 (2)

The House Judiciary Committee conducted a hearing on World IP Day on “International Patent Issues: Promoting a Level Playing Field for American Industry Abroad.”  BIO submitted written comments for the record highlighting the unique patenting challenges that biotechnology companies face around the world. “To fully understand what is needed to level the playing field for the biotechnology sector in international markets, one must understand the intellectual property (IP) needs of the biotechnology sector.  Biotechnology innovation Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Convention 2012: Biotech IP and Tech Transfer Sessions

US PTO

Recent court decisions and ongoing implementation of the America Invents Act are certain to impact the life sciences industry. The 2012 BIO International Convention will feature an educational track devoted to Biotech Patenting and Tech Transfer to discuss legal and legislative developments and how they are likely to impact biotech companies.   This year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA. Recent Developments Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , ,

New Patented Drugs Save Us All Money and Help Those in Dire Need

Money and Savings

New patented drugs actually save the United States and its citizens lots of money. In fact, new drugs save 7 times more in non-drug spending than they cost.  Those savings come as new drugs result in reduced hospital and nursing home admissions which far exceed the cost of using newer drugs.  New patented prescription drugs can also reduce the need for expensive surgeries and hospital stays. This data clearly articulates that the cost of treating Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,